Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients eligible for this inclusion in this study have to fulfil all the following criteria: * Age 18 years * Written informed consent of the patient * Sufficient fluency in German language skills to complete all questionnaires of the study without external assistance * Treatment-related, immune-related vitiligo-like depigmentation of at least 5% body surface area of one region (face or one upper or lower extremity or front or back side of the trunk) * Female participants must use effective contraceptives, either: An ovulation-inhibiting method (e.g., pill, injectable, implant, patch, or vaginal ring) or an intrauterine device (IUD). Contraception should extend one week post-study. If pregnancy occurs during or within one week after the study, participants should notify the overseeing physician immediately. * During participation in the study and up to one week afterwards, male participants may only have sexual intercourse with condoms. Female partners of male participants must use a highly effective contraceptive method during the partner's participation in the study and for up to 1 week afterwards Exclusion Criteria: Patients fulfilling any of the following criteria are not eligible for the inclusion in this study: * Acute psychiatric illness (except mild to moderate depression) * Contraindications to ruxolitinib, e.g. known hypersensitivity or allergy * Use of topical glucocorticosteroids, topical calcineurin inhibitors, UV light therapy, therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine are not allowed during the study period (no wash out period required). * Women who are pregnant or breast feeding * Intention to become pregnant during the course of the study * Known or suspected non-compliance, drug or alcohol abuse. * Patients with an active, serious infection, including localized infections. * Inability to follow the procedures of the study due to language problems, psychological disorders, dementia of the participant. * Participation in another trial with topical or oral ruxolitinib within the 30 days preceding and during the present study. * Simultaneously participation in clinical trials with intervention with a drug other than ruxolitinib (except registry studies) * Previous enrolment into the current study. * Enrolment of the investigator, his/her family members, employees and other dependent persons.